Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Forxiga
Active substance
dapagliflozin propanediol monohydrate
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Procedure number
EMEA/H/C/002322/II/0071
Regulatory outcome
Variation
DHPC type
Type II variation
Human ATC code
A10BK01
Dissemination date
11/11/2021

How useful was this page?

Add your rating